1. STEM BANK 2. THERAPY 3. MEDICAL DEVICES 4. CERTS TRAINING 5. LAB 6. STEMDATA 7. CLINICAL TRIALS 8. ACQUISITION BY BIG PHARMA 9. EXPANSION CRITERIA
EACH SECTOR ABOVE IS UNIQUE AND CANNOT BE MEASURED BY STANDARD P/E ETC.. WHY?
Amag Pharma..buy world's largest stem..bank..$700 million
..and that it was on the hunt for more deals.
..Advisors Deutsche Bank and Jefferies LLC served as financial advisors to AMAG on the transaction. AMAG's legal advisor is Goodwin Procter LLP. CBR's and GTCR's legal advisor is Kirkland & Ellis LLP. Jefferies Finance LLC and Barclays are serving as initial lenders and lead arrangers for the committed debt financing, and Jones Day served as their legal advisor.
What Does Pfizer Have to do with the World of Stem Cells?
Most people would not call Pfizer a stem cell company, much less a cell therapy company, a regenerative medicine company, or even a biotech company. Pfizer is viewed as a “classic and traditional” pharmaceutical company, best known for its blockbuster sales of drugs, such as Lipitor and Viagra. While Pfizer is largely a drug company, the company has expressed periodic interest in the stem cell sector.
GSCG established.. alliance.. HANK Bioengineering..Shenzhen, China
Shenzhen HANK is a biotechnology company established in 2013 by Zhang, an award-winning scientist, microbiologist and virologist, to integrate research, development, production, and sales of biomedical products. Zhang worked at the U.S. Centers for Disease Control from 1991 to 1993, the U.S. National Institute of Health (NIH) from 1993 to 1994, and the U.S. Food and Drug Administration from 1995 to 2013 in various research positions including National Research Center (NRC) senior associate..
....In 2013, Dr. Zhang expanded on his work in stem cell research and development by launching HANK Bioengineering Co. Ltd. in Shenzhen, China. HANK is a 4,300 square foot (400 square meters) CFDA certified cGMP facility affiliated with HANK Bioengineering Institute’s Cell Biology and Molecular Immunology Laboratories. HANK has established close collaborations with more than five hospitals in China for clinical applications of its cell therapy products.